The Priority Review

Tag

BioMarin

1 story

  1. Clinical trials

    BioMarin presents new VOXZOGO data at ASBMR 2026

    BioMarin will present new data from 13 studies, including a randomized, double-blind, placebo-controlled trial on VOXZOGO's effect on foramen magnum and craniocervical junction growth in children with achondroplasia. The company will also share data on the investigational long-acting medicine BMN 333 and on VOXZOGO's potential use in hypochondroplasia, for which it has submitted a supplemental New Drug Application.